Physician profile
David Hamrock
NPI 1215990288
$19,366.42
in general payments reported to CMS, 2019-2025
39 companies · $2,323 in 2025
The $2,323 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,807 · 2020: $2,110 · 2021: $2,915 · 2022: $3,488 · 2023: $2,252 · 2024: $2,471 · 2025: $2,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,736 · Education: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,735.80 |
| Education | $309.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,536.00 | 2019-2025 | |
| Janssen Biotech, INC. | $2,739.90 | 2019-2025 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $1,545.14 | 2019-2025 | |
| Lilly USA, LLC | $1,335.20 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $1,073.54 | 2019-2025 | Odomzo, Blu-U |
| Ucb, INC. | $939.78 | 2019-2025 | Bimzelx |
| Genzyme Corporation | $910.47 | 2019-2025 | |
| Leo Pharma INC. | $720.28 | 2020-2025 | Adbry, Spevigo |
| Janssen Scientific Affairs, LLC | $715.85 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $612.37 | 2019-2025 | Dupixent, Libtayo |
| Mallinckrodt Hospital Products INC. | $605.49 | 2020-2023 | Acthar |
| Amgen INC. | $503.26 | 2019-2025 | Otezla, Otezla |
| Mallinckrodt Enterprises LLC | $482.34 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $391.62 | 2022-2024 | Sotyktu |
| Genentech USA, INC. | $248.25 | 2019-2025 | Xolair |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.33 | 2022-2025 | Spevigo, Cyltezo |
| Sanofi-Aventis U.S. LLC | $99.99 | 2020 | |
| Celgene Corporation | $71.00 | 2019 | |
| Organogenesis INC. | $65.32 | 2024-2025 | Simplimax, Puraply Wound Matrix |
| Pfizer INC. | $63.83 | 2019 | |
| Incyte Corporation | $57.94 | 2021-2023 | Opzelura |
| Biocon Biologics INC | $46.77 | 2024 | Hulio |
| Convatec INC. | $40.96 | 2024-2025 | |
| Galderma Laboratories, L.P. | $39.94 | 2024-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.45 | 2021-2025 | Siliq, Jublia, Cabtreo |
| Fresenius Kabi USA, LLC | $34.24 | 2023 | Idacio |
| Qiagen, LLC | $30.69 | 2024 | |
| Prugen, INC. Pharmaceuticals | $24.42 | 2019 | |
| Mylan Institutional INC. | $23.04 | 2023 | Hulio |
| Cipher Pharmaceuticals US LLC | $21.24 | 2025 | Spinosad, Natroba |
| Dermavant Sciences, INC. | $19.86 | 2023 | Vtama |
| Alexion Pharmaceuticals, INC. | $19.34 | 2024 | Strensiq |
| Arcutis Biotherapeutics, INC. | $18.04 | 2023 | |
| Dermira, INC. | $16.89 | 2019 | |
| Ets Wound Care LLC | $16.53 | 2025 | Mirragen Advanced Wound Matrix |
| Sandoz INC. | $15.87 | 2024 | Hyrimoz |
| Merck Sharp & Dohme LLC | $14.80 | 2019 | |
| Botanix Sb INC | $14.43 | 2025 | Sofdra |
| Dusa Pharmaceuticals, INC. | $14.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hamrock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.